ROSUVASTATIN AND EZETIMIBE

ROSUVASTATIN AND EZETIMIBE- rosuvastatin calcium and ezetimibe tablet
SCOV3 LLC

1 INDICATIONS AND USAGE

Rosuvastatin and ezetimibe tablets is indicated in adults:

  • As an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).
  • Alone or as an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage and Administration Information

  • Swallow rosuvastatin and ezetimibe tablets whole at any time of day, with or without food. Do not crush, dissolve, or chew tablets.
  • The dosage range is 5 mg/10 mg to 40 mg/10 mg once daily.
  • The recommended dose of rosuvastatin and ezetimibe tablets depends on a patient’s indication for usage, LDL- C, and individual risk for cardiovascular events.
  • The starting dosage for patients switching to rosuvastatin and ezetimibe tablets from co-administration of a statin and ezetimibe is based on an equivalent dose of rosuvastatin and 10 mg of ezetimibe.
  • Assess LDL-C when clinically appropriate, as early as 2 weeks after initiating rosuvastatin and ezetimibe tablets, and adjust the dosage if necessary.

2.2 Recommended Dosage in Asian Patients

Initiate rosuvastatin and ezetimibe tablets at 5 mg/10 mg daily due to increased rosuvastatin plasma concentrations. Consider the risk/benefit when treating Asian patients not adequately controlled at doses up to 20 mg/10 mg once daily [see Warnings and Precautions (5.1), Use in Specific Populations (8.8), and Clinical Pharmacology (12.3)].

2.3 Recommended Dosage in Patients with Renal Impairment

In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m2) not on hemodialysis, the recommended starting dosage is 5 mg/10 mg once daily and should not exceed 10 mg/10 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].

There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

2.4 Dosage and Administration Modifications Due to Drug Interactions

  • In patients taking a bile acid sequestrant, administer rosuvastatin and ezetimibe tablets at least 2 hours before or 4 hours after the bile acid sequestrant [see Drug Interactions (7.2)].
  • When taking rosuvastatin and ezetimibe tablets with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin and ezetimibe tablets at least 2 hours before the antacid [see Drug Interactions (7.2)].
  • Concomitant use of rosuvastatin and ezetimibe tablets with the following drugs requires dosage modifications of rosuvastatin and ezetimibe tablets [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].

Darolutamide
Do not exceed rosuvastatin and ezetimibe tablets 5 mg/10 mg once daily.

Regorafenib
Do not exceed rosuvastatin and ezetimibe tablets 10 mg/10 mg once daily.

Antiviral MedicationsConcomitant use of sofosbuvir/velpatasvir/voxilaprevir and ledipasvir/sofosbuvir with rosuvastatin and ezetimibe tablets is not recommended.

In patients taking simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, atazanavir/ritonavir, and lopinavir/ritonavir initiate rosuvastatin and ezetimibe tablets at 5 mg/10 mg once daily. Do not exceed rosuvastatin and ezetimibe tablets 10 mg/10 mg once daily.

No dose adjustment is needed for concomitant use with fosamprenavir/ritonavir or tipranavir/ritonavir.

3 DOSAGE FORMS AND STRENGTHS

Rosuvastatin and ezetimibe tablets are available as follows:

Strength Contents Description
5 mg/10 mg rosuvastatin 5 mg/ezetimibe 10 mg round pink biconvex tablets with “5” embossed on one side
10 mg/10 mg rosuvastatin 10 mg/ezetimibe 10 mg round pink biconvex tablets with “AL” embossed on one side
20 mg/10 mg rosuvastatin 20 mg/ezetimibe 10 mg round pink biconvex tablets with “II” embossed on one side
40 mg/10 mg rosuvastatin 40 mg/ezetimibe 10 mg round pink biconvex tablets with “77” embossed on one side

4 CONTRAINDICATIONS

Rosuvastatin and ezetimibe tablets is contraindicated in patients with:

  • Acute liver failure or decompensated cirrhosis.
  • Hypersensitivity to rosuvastatin, ezetimibe, or any excipients in rosuvastatin and ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, and erythema multiforme have been reported [see Adverse Reactions (6)].

5 WARNINGS AND PRECAUTIONS

5.1 Myopathy and Rhabdomyolysis

Rosuvastatin and ezetimibe tablets may cause myopathy (muscle pain, tenderness, or weakness with creatine kinase [CK] above ten times the upper limit of normal) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin.
Risk Factors for Myopathy
Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs including other lipid-lowering therapies, and higher rosuvastatin and ezetimibe tablets dosage; Asian patients on rosuvastatin and ezetimibe tablets may be at higher risk for myopathy [see Drug Interactions (7.1) and Use in Specific Populations (8.8)]. The myopathy risk is greater in patients taking rosuvastatin and ezetimibe tablets 40 mg/10 mg daily compared with lower rosuvastatin and ezetimibe tablets dosages.

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis
The concomitant use of rosuvastatin and ezetimibe tablets with cyclosporine or gemfibrozil is not recommended. Rosuvastatin and ezetimibe tablets dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration (2.4)]. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)].

Discontinue rosuvastatin and ezetimibe tablets if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Muscle symptoms and CK increases may resolve if rosuvastatin and ezetimibe tablets is discontinued. Temporarily discontinue rosuvastatin and ezetimibe tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis, e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy.

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the rosuvastatin and ezetimibe tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.